Bioton SA is a leading biotechnology company that represents a strong set of values and corporate philosophy. The company values innovation, research, and development to provide cutting-edge solutions in the field of biotechnology. Bioton SA focuses on providing high-quality healthcare products and services to improve people's lives. With a commitment to excellence and a customer-centric approach, Bioton SA aims to deliver value to its stakeholders. The company's philosophy centers around sustainable growth, ethical practices, and fostering partnerships to drive success. Bioton SA's dedication to scientific advancement and ethical business conduct makes it a trusted name in the biotechnology industry.

Bioton SA is primarily present in Poland, where it is headquartered. Additionally, Bioton SA has a significant presence in the European market, specifically in countries such as Germany, France, and the United Kingdom.

Bioton SA, a leading pharmaceutical company, has achieved remarkable milestones throughout its existence. The company garnered global recognition for its groundbreaking advancements in the field of biotechnology. Bioton SA successfully introduced innovative pharmaceutical products, including insulin and other life-saving medications, revolutionizing the treatment of diabetes and various other medical conditions. Moreover, the company's dedicated research and development efforts have enabled Bioton SA to expand its product portfolio and consistently deliver high-quality therapeutic solutions to meet the growing healthcare needs of patients worldwide. Bioton SA's commitment to excellence and continuous innovation has established it as a prominent leader in the pharmaceutical industry.

Bioton SA is a renowned pharmaceutical company with a rich history and background. Established in 1989, Bioton SA has become a pioneer in the field of biotechnology and specializes in the development, production, and marketing of innovative pharmaceuticals. With its headquarters in Poland, Bioton SA has successfully expanded its operations globally. The company has made significant contributions to the medical industry through its cutting-edge research and development efforts, particularly in the fields of diabetes and human insulin production. Bioton SA continuously strives to provide high-quality products and improve global healthcare standards, solidifying its position as a leading player in the pharmaceutical sector.

The main competitors of Bioton SA in the market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, and Merck & Co., Inc.

Bioton SA is primarily active in the biotechnology and pharmaceutical industries.

The business model of Bioton SA revolves around the development, manufacturing, and distribution of innovative biopharmaceutical products. Bioton SA specializes in the production of recombinant human insulin and insulin analogs, addressing the needs of diabetic patients worldwide. The company focuses on research and development activities to continuously improve their products and expand their portfolio. Bioton SA strives to provide high-quality and affordable healthcare solutions, catering to the growing demand for diabetes treatment options. With their strong commitment to innovation and patient care, Bioton SA aims to establish itself as a leading player in the biopharmaceutical industry.

Bioton için şu anki KGV hesaplanamıyor.

Bioton için mevcut KUV şu anda hesaplanamıyor.

AlleAktien Kalite Skoru şu anda Bioton için hesaplanamıyor.

Bioton için şu an ciro hesaplanamıyor.

Bioton için şu anda kar hesaplanamıyor.

Bioton SA is a Polish biotechnology company that specializes in the development and production of biotechnological and medical products. The company's business model is focused on advancing innovation and research in biotechnology and producing high-quality products suitable for both the Polish and international markets. The company is divided into three divisions: medicine, agriculture, and industry, each offering its own products and services. In medicine, Bioton SA offers a wide range of products for prevention, diagnosis, and therapy of various diseases, including diagnostic kits, vaccines, and therapeutics. In the agriculture division, the company aims to improve global food production through the development and production of animal feed and biotechnological enzymes, which enhance the nutrition of livestock and increase the nutritional value of meat, milk, and eggs. In the industry division, Bioton SA develops biotechnological enzymes and processes used in the food and beverage industry, as well as other industries such as textiles and paper, to improve production efficiency and product quality. The company emphasizes its strong presence in research and development, with a team of highly qualified scientists and technicians dedicated to researching and developing new products. Bioton SA also invests heavily in collaboration with universities and research institutes to stay at the forefront of technology and drive continuous innovation. Additionally, the company highlights its strong presence in the international market, with branches in several countries in Europe, Asia, and South America. It also operates several subsidiaries specialized in selling and marketing products in specific markets. Overall, Bioton SA's business model is focused on producing high-quality products while promoting the growth and development of the biotechnology industry. The company emphasizes its presence in various industries and markets and its ability to conduct innovation and research at the highest level.

Bioton, yılda kez dağıtılmak üzere 0 PLN tutarında temettü ödemektedir.

Bioton için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Bioton şirketinin ISIN kodu PLBIOTN00029’dir.

Bioton 'nin WKN'si A0D9SD 'dir.

Bioton için Ticker BIO.WA’dir.

Son 12 ay içerisinde Bioton, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Bioton, tahmini olarak 0 PLN tutarında bir temettü ödemesi yapacak.

Bioton şirketinin mevcut temettü verimi .

Bioton dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Bioton, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 PLN tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Bioton, 'Sağlık' sektörüne atanmıştır.

Son Bioton tarihinde 0 PLN tutarındaki en son temettüyü alabilmek için, hisseyi 01.08.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 01.08.2024 olarak gerçekleşti.

2023 yılında Bioton tarafından 0 PLN olarak temettüler dağıtıldı.

Bioton hisselerinin temettüleri PLN olarak dağıtılır.